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Aims Anticoagulants are the mainstay treatment for stroke prevention in patients with non-valvular atrial fibrillation
(NVAF), and the CHA2DS2-VASc score is widely used to guide anticoagulation therapy in this cohort. However,
utility of CHA2DS2-VASc in NVAF patients is debated, primarily because it is a vascular scoring system, which does
not incorporate atrial fibrillation related parameters. Therefore, we conducted a meta-analysis to estimate the dis-





PubMed and Embase databases were searched till June 2020 for published articles that assessed the discrimination
ability of CHA2DS2-VASc, as measured by C-statistics, during mid-term (2–5 years) and long-term (>5 years)
follow-up. Summary estimates were reported as random effects C-statistics with 95% confidence intervals (CIs).
Seventeen articles were included in the analysis. Nine studies (n = 453 747 patients) reported the discrimination
ability of CHA2DS2-VASc in NVAF patients, and 10 studies (n = 138 262 patients) in patients without NVAF.
During mid-term follow-up, CHA2DS2-VASc predicted stroke with modest discrimination in the overall cohort
[0.67 (0.65–0.69)], with similar discrimination ability in patients with NVAF [0.65 (0.63–0.68)] and in those without
NVAF [0.69 (0.68–0.71)] (P-interaction = 0.08). Similarly, at long-term follow-up, CHA2DS2-VASc had modest dis-
crimination [0.66 (0.63–0.69)], which was consistent among patients with NVAF [0.63 (0.54–0.71)] and those with-
out NVAF [0.67 (0.64–0.70)] (P-interaction = 0.39).
...................................................................................................................................................................................................
Conclusion This meta-analysis suggests that the discrimination power of the CHA2DS2-VASc score in predicting ischaemic
stroke is modest, and is similar in the presence or absence of NVAF. More accurate stroke prediction models are
thus needed for the NVAF population.
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Introduction
European Society of Cardiology (ESC) and the American College of
Cardiology/American Heart Association (ACC/AHA) guidelines
recommend the use of CHA2DS2-VASc score to predict the risk of
ischaemic stroke and subsequently guide oral anticoagulation use in
patients with non-valvular atrial fibrillation (NVAF).1–3 However, the
CHA2DS2-VASc is solely based on clinical risk factors (e.g. age,
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hypertension, diabetes, vascular disease) (Supplementary material
online, Table S1) that are also known to increase the risk of stroke in
patients without NVAF.4,5 In addition, CHA2DS2-VASc does not con-
sider key variables that are increasingly shown to impact the risk of is-
chaemic stroke in the setting of NVAF [duration of AF, left atrium/left
atrial appendage (LAA) size, function, and morphology, cardiac bio-
markers, and electrographic markers]. Thus, it has been suggested
that this model may not be specific for NVAF-related ischaemic
stroke, and may be equally predictive in a patient population without
AF.4 In this meta-analysis, we pooled currently available data to esti-
mate the discrimination ability of CHA2DS2-VASc in predicting
ischaemic stroke among patients with and without NVAF.
We hypothesized that if the CHA2DS2-VASc score is specifically pre-
dictive of NVAF-related ischaemic strokes, its discrimination ability
(C-statistic) would be significantly higher in patients with NVAF than
in patients without NVAF.
Methods
This study is reported in accordance with the Preferred Reporting Items
for Systematic review and Meta-Analyses (PRISMA) guidelines.6
The PubMed and Embase databases were searched from inception up till
June 2020 for published articles that assessed the prognostic value of the
CHA2DS2-VASc score. A detailed search strategy for each database is
provided in Supplementary material online, Table S2. Other data sources
including bibliographies of relevant articles and proceedings of scientific
meetings. No language or time restrictions were set. All the articles were
imported into EndNote X9 (Clarivate Analytics, Thomson Reuters
Corporation) and duplicates were removed. Articles were initially
screened based on title and abstracts, after which full texts were
evaluated.
Studies were included if they (i) used the CHA2DS2-VASc score to
predict mid-term (2–5 years) and/or long-term (>5 years) risk of ischae-
mic stroke; (ii) reported the C-statistic (also known as area under the
curve or AUC) as a measure of discrimination. Abstracts and unpublished
studies were excluded. Included studies were divided into two groups
based on whether they included patients with or without AF at baseline.
Studies were excluded if they comprised of a mixed population of
patients with and without NVAF or if they evaluated the risk of thrombo-
embolic events other than ischaemic stroke. Studies with follow-up
of <2 years were also excluded as only a few studies reported data at
<2-year follow-up (five NVAF; two without AF), and the authors were of
consensus that a follow-up of <2 years had limited predictive value. The
following data were extracted: study characteristics, baseline characteris-
tics of patients, and C-statistic [with their corresponding 95% confidence
intervals (CIs) or standard errors (SEs)]. The search and data extraction
were carried out independently by two reviewers (I.S. and J.A.), and a
third reviewer (M.S.U.) was consulted in case of discrepancies. Data ex-
traction was conducted in accordance to the CHARM (Critical Appraisal
and Data Extraction for Systematic Reviews of the Prediction Modelling
Studies) checklist.7 The data underlying this article are available in the
article and in its Supplementary material online.
Discrimination (measured using the C-statistic) is defined as an assess-
ment of the ability of a risk prediction model to differentiate between
subjects who will develop an outcome (in this case, stroke) when
compared with those who will not.8 C-statistic values range from 1.0 (per-
fect agreement between model-estimated risk and observed events) to
0.5 (random concordance). We defined the discrimination ability of the
model based on recent publication as (i) 0.81–0.90 = good discrimination;
(ii) 0.71–0.80 = fair discrimination; (iii) 0.61–0.70 = modest/poor discrim-
ination; and (iv) 0.50–0.60 = very poor/almost no association.9 Review
Manager (Version 5.5; Cochrane Collaboration, Oxford, UK) and STATA
(v.11; TX, USA) were used to perform the statistical analysis. The generic
inverse variance weighted random effects method was used for pooling
C-statistic and corresponding SEs from each study. We used random
effects model to account for any potential statistical heterogeneity.10
When SEs were not available, they were calculated from the confidence
intervals. The v2 test and associated P-interaction value were used to test
for any statistically significant differences between the NVAF and no
NVAF subgroups. Given that the CHA2DS2-VASc score is generally used
to predict the risk of stroke prior to anticoagulation therapy, we con-
ducted a sensitivity analysis using only studies in which none of the
patients received anticoagulation. The refined Prediction model Risk of
Bias Assessment Tool (PROBAST) was used to assess the risk of bias in
the included studies.11 The Begg’s test was performed to evaluate publi-
cation bias in our study. A P-value <0.05 was considered significant in all
cases.
Results
Of 4469 articles, a total of 17 studies met selection criteria for
meta-analysis (Figure 1). Studies excluded during full-text review and
reasons for their exclusion are presented in Supplementary material
online, Table S3. Of the included studies, 9 studies (n = 453 747
patients) reported discrimination ability in NVAF patients, and
10 studies (n = 138 262 patients) reported discrimination ability in
patients without NVAF. The study characteristics are presented in
Supplementary material online, Tables S4 and S5. Application of the
PROBAST scale demonstrated that the large majority of studies
included in this meta-analysis were at minimal risk of bias and had low
concern regarding applicability (Supplementary material online,
Table S6). Begg’s test demonstrated no significant publication bias in
the included studies (Supplementary material online, Table S7).
Discriminatory power of CHA2DS2-
VASc at mid-term follow-up (2–5 years)
Meta-analysis of 12 studies [7 NVAF studies (n = 446 274 patients); 5
studies without NVAF (n = 108 598 patients)] at mid-term follow-up
revealed that the CHA2DS2-VASc model had limited discriminatory-
power to predict ischaemic stroke [summary estimate: 0.67 (0.65–
0.69)] (Figure 2). Upon subgroup analysis, this finding was consistent
in patients with NVAF [0.65 (0.63–0.68)] and among those without
NVAF [0.69 (0.68–0.71)] (P-interaction = 0.08).
Discriminatory power of CHA2DS2-
VASc at long-term follow-up (>5 years)
Similarly, meta-analysis of seven studies [two NVAF studies (n = 7473
patients); five studies without NVAF (n = 29 664 patients)] at
long-term follow-up revealed modest discriminatory power of
CHA2DS2-VASc to predict ischaemic stroke [summary estimate:
0.66 (0.63–0.69)] (Figure 3). This effect was also consistent among
NVAF patients [0.63 (0.54–0.71)] and among those without NVAF
[0.67 (0.64–0.70)] (P-interaction = 0.39).



























Sensitivity analysis to exclusively study
patients who did not receive
anticoagulation during the study period
Three studies included in our mid-term analysis did not report
excluding patients receiving warfarin from their analysis.12–14 Upon
removal of these studies, the results remained similar. Our sensitivity
analysis included 473 832 patients (n = 436 547 NVAF patients;
n = 37 285 without NVAF patients). The overall discrimination was
modest (summary estimate: 0.69 [0.67–0.70]). Similarly, both the
NVAF (0.68 [0.67–0.70]) and without NVAF (0.68 [0.67–0.69])
subgroups still had modest discrimination, with no significant differ-
ence between the two groups (P-interaction = 0.30).
Sensitivity analysis at long-term follow-up was not possible as ma-
jority of the studies with >5-year follow-up did not describe how
data of patients receiving warfarin were handled during analysis.
Discussion
Assessment of ischaemic stroke risk has become a central element in
the management of NVAF. Although many risk schemes have been
proposed, tested, and validated in external cohorts, the CHA2DS2-
Figure 1 PRISMA flow diagram of the included studies.















..VASc score remains the most common risk model used worldwide
likely due to its availability and simplicity.4,16 Indeed, the CHA2DS2-
VASc score has become increasingly popular in recent years as a use-
ful risk stratification tool for various outcomes and in a variety of
clinical settings.4,17–20 In addition to AF, the CHA2DS2-VASc score
has recently been observed as a useful predictor for determining ad-
verse outcomes, such as mortality, risk of stroke, major adverse car-
diocerebral vascular events, and thromboembolic events in high-risk
Figure 2 Discriminatory power of CHA2DS2-VASc at mid-term follow-up (2–5 years). AUC, area under the curve; CI, confidence interval; SE,
standard error.
Figure 3 Discriminatory power of CHA2DS2-VASc at long-term follow-up (>5 years). AUC, area under the curve; CI, confidence interval; SE,
standard error.

































































































patient cohorts, such as those with acute myocardial infarction,
chronic obstructive lung disease, or heart failure.13,20 However, at
the same time, concerns have been raised about the specificity of the
CHA2DS2-VASc in predicting NVAF-related stroke considering:
(i) the growing literature on the utility of the CHA2DS2-VASc score
to predict ischaemic stroke in the absence of NVAF,4,13,21 and (ii) the
fact that this score neither accounts for several key NVAF-specific
factors that are known to impact the risk of ischaemic stroke, such as
the burden of AF, the size and function of the left atrium (LA) and
LAA, nor does it consider the presence of competing risk factors
such as complex aortic plaque or carotid stenosis which is associated
with double the risk of stroke in patients with NVAF.4,21 We hence
hypothesized that if the CHA2DS2-VASc score is a powerful tool in
predicting ischaemic stroke related to NVAF, its discriminative power
(C-statistic) would be much higher in patients with NVAF vs. those
without NVAF.
Our current meta-analysis including 600 000 patients revealed
that the discrimination ability of the CHA2DS2-VASc risk score was
not different among patients with or without NVAF, suggesting that
this risk score might not be specific for the prediction of NVAF-
related stroke. Our findings raise an important question: does NVAF
have an independent impact on stroke risk, or does the risk of stroke
stem from the common vascular risk factors and structural cardiac
and vascular abnormalities that accompany NVAF? Although the as-
sociation between anticoagulation and reduction of the incidence of
ischaemic stroke in patients with NVAF is firmly established, the
underlying mechanistic basis of stroke in patients with NVAF is com-
plex and considering it as an independent and sole cause of stroke
has therefore been challenged.22 For instance, several studies have
shown that the increased risk of ischaemic stroke among patients
with left atrial abnormalities (compared with patients with normal
left atria) persists after adjusting for the presence of NVAF.22–25
In addition, if NVAF was the sole cause of stroke, restoration of sinus
rhythm would have reduced the risk of ischaemic stroke and miti-
gated the need for lifelong anticoagulation.22,26 Nonetheless, a large
number of studies have documented a persistent risk of stroke
despite maintenance of sinus rhythm for several years after drug-,
catheter-, or surgical-rhythm restoration.26 Thus, the current guide-
lines recommend continuation of anticoagulation after restoration of
sinus rhythm due to the large body of evidence. Indeed, these obser-
vations formed the basis of the ‘atrial cardiopathy’ concept, which
suggests that NVAF may be merely a manifestation of a global
process that increases the risk of stroke rather than an independent
entity.
The modest C statistics shown in our analysis are in-agreement
with a large prior meta-analysis that documented a modest perform-
ance of CHA2DS2-VASc in predicting risk of stroke in patients with
NVAF.27 Although other studies have documented a higher C-statis-
tic for the CHA2DS2-VASc score, those studies combined stroke and
transient ischaemic attacks, and were more prone to the limitations
associated with ascertainment of transient ischaemic attacks.28–30
Indeed, the original study that led to the wide spread adoption of the
CHA2DS2-VASc score as a key risk stratification tool in patients with
NVAF showed poor discrimination power of the score (C-statistic =
0.61).31
Our findings have important implications. The CHA2DS2-VASc
score is used not only to assess the need for stroke-preventive ther-
apy, but also the type of therapy required.32 For example, in practice,
left atrial appendage closure (LAAC) is mostly conducted on patients
with a relatively high CHA2DS2-VASc score and a contraindication to
oral anticoagulation.33 Studies from single-arm registries of LAAC
often claim benefit of the procedure based on lower observed rates
of stroke compared with the rate predicted by CHA2DS2-VASc or a
similar score.34–37 This comparison is clearly problematic given that
the CHA2DS2-VASc score relates poorly to incidence of stroke, as
demonstrated by our study. Thus, more accurate risk assessment
tools are required for better patient management as well as more
reliable research within the AF domain.
Future stroke prediction models should incorporate AF-specific
factors such as LA and LAA anatomy and morphology, cardiac
biomarkers, and electrographic markers. There is evidence that inclu-
sion of these factors may increase the predictive performance of
stroke risk prediction models.4 For example, it has been documented
that each 10 mm increase in LA size increases the risk of stroke by
40–100%,38 while large and/or less mobile LAA’s are associated with
up to 6-fold increase in the adjusted risk of stroke.39 Increase in LA
size is also predictive of risk of recurrent cardioembolic or crypto-
genic stroke in patients with non-valvular atrial fibrillation (NVAF).40
Moreover, patients with higher values of troponin-I, troponin-T, and
N-terminal pro-B type natriuretic peptide are more susceptible to
stroke when compared with those with lower values.41 Similarly, an
abnormal P-wave axis is also associated with higher odds of stroke
risk in patients with paroxysmal AF.42
The findings of our study further highlight the need for better
understanding of the pathological and temporal associations between
vascular risk factors, NVAF, atrial abnormalities, and ischaemic
stroke. In addition, these findings underscore the need for more
comprehensive tools to help clinicians predict the risk of ischaemic
stroke both in patients with NVAF and those without NVAF.
Limitations
Our meta-analysis has a number of limitations which need to be
considered while interpreting its results. First, this is an aggregate-
level meta-analysis and does not account for participant level in-
formation. Second, some validation studies were excluded from
our analysis as relevant data were not reported. Third, some of
our results had significant heterogeneity, which may be perceived
as an important limitation. However, the high I2 in our analysis
stems from the variability in sample sizes of component studies of
this meta-analysis. This is a known observation in high-powered
meta-analyses and is not deemed clinically significant, especially if
effect sizes of included studies are similar, as in our analysis.43
Fourth, considering the observational nature of these studies,
confirmation of freedom from NVAF in studies assessing stroke
risk in the absence of AF may be limited. Fifth, there may have
been patients with subclinical AF in studies without NVAF, which
could have contributed to some bias. However, the prevalence of
subclinical AF ranges from 2% to 10% in the elderly age group,
hence we do not expect this to considerably affect our
results.44,45 Sixth, majority studies did not specify patients via
types of AF (paroxysmal or non-paroxysmal), however, since the

































































































risk of stroke does not differ between these two patient cohorts,
the type of AF likely does not confound the results of our
analysis.46,47 Seventh, since this is an analysis of observational
data, residual confounding is a possibility. And lastly, our manu-
script shows that the CHA2DS2-VASc score has limited positive
predictive value. However, this study did not account for negative
predictive value of CHA2DS2VASc score.
Conclusion
This large meta-analysis suggests that the discrimination ability of
CHA2DS2-VASc score in predicting ischaemic stroke is not signifi-
cantly different in the presence or absence of NVAF. These findings
highlight the limitations in our current risk stratification models, and
the need for deeper understanding of the association between NVAF
and ischaemic stroke.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology online.
Conflict of interest: none declared.
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The data underlying this article are available in the article and in its
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